Mira Pharmaceuticals 주식 (NASDAQ: MIRA)

에 대한 최신 뉴스 Mira Pharmaceuticals (NASDAQ:MIRA) 주식

Mira Pharmaceuticals

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

Exclusives

Tech

Trading Ideas

ETFs

AAPL

AMZN

CRWD

KOSS

LGVN

MIRA

MSFT

NUZE

NVDA

PLTR

SERV

SMCI

SOBR

TSLA

ZAPP

각 거래일에는 트레이더들이 전체 시장과 개별 종목들에 대한 최신 뉴스를 볼 수 있는 소스의 하나인 Benzinga Pro에 수백 개의 헤드라인과 보도 자료가 제공된다. 2024년 7월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식을 살펴보겠다. 현재 가격과 연간 실적은 8월 1일을 기준으로 하며 배당금은 포함되지 않는다. 4월 검색결과는 추적되지 않았다.

단독: 7월 벤징가 프로에서 가장 많이 검색된 상위 20개 종목 - 테슬라, 엔비디아, CRWD 순위는?

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals Inc

MIRAI Corp

MIRAIT One Corp

MIRAMAR RESOURCES LTD by MIRAMAR RESOURCES LTD

MIRATI THERAPEUTICS INC COM

MIRACLE ENTMT INC by Miracle Entertainment Inc.

Miracle Entertainment Inc

MIRAGE ENERGY CORP by Mirage Energy Corporation

Mirage Energy Corp

MIRAMAR HOTE & INVST CO by Miramar Hotel & Investment Co., Ltd.

Miramar Hotel & Investment Co Ltd

TAKARA LEBEN CO LTD by Takara Leben Co., Ltd.

Mirarth Holdings Inc

MIRASOL RESOURCES LTD by Mirasol Resources Ltd.

Mirasol Resources Ltd

Miratap Inc

MIRAVANT MEDICAL TECHS by Miravant Medical Technologies

Miravant Medical Technologies

President-elect Donald Trump has picked hedge fund executive Scott Bessent as the U.S. Treasury Secretary.
What Happened: Bessent, 62 and founder of Key Square Group, was a leading candidate, <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42091821/could-donald-trumps-potential-treasury-secretary-be-out-of-his-depth-on-crypto-policy-polymarket-traders-just-cant-decide-on-a-favorite">competing with</a> former Fed Governor Kevin Warsh and private equity executive Marc Rowan.
While sharing the decision on Friday via his social media platform Truth Social, Trump lauded Bessent as "one of the World's foremost International Investors and Geopolitical and Economic Strategists."
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22205557/Screenshot-2024-11-23-at-7.25.49%E2%80%AFAM-900x1024.png" alt="" class="wp-image-661913" /><figcaption class="wp-element-caption">Source: Truth Social</figcaption></figure>
See Also: <a href="https://www.benzinga.com/news/legal/24/11/42147981/trumps-hush-money-sentencing-delayed-as-legal-immunity-debate-escalates">Trump&#8217;s Hush Money Sentencing Delayed As Legal Immunity Debate Escalates</a>
Bessent is known for his support of gradual tariffs and deregulation, aligning with Trump&#8217;s economic vision, which includes reviving manufacturing and achieving energy independence.
Despite his previous role as chief investment officer for George Soros' fund, Trump expressed confidence in Bessent&#8217;s ability to improve U.S. competitiveness and address trade imbalances.
Why It Matters: As Treasury Secretary, Bessent will replace outgoing Secretary Janet Yellen, overseeing financial institutions and combating financial crimes at a time when <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42140842/sp-500-faces-volatile-2025-as-inflation-boom-could-return-bank-of-america-strategist">the national debt has ballooned to $36 trillion</a>.
According to <a href="https://www.benzinga.com/government/regulations/24/11/41909846/trumps-treasury-pick-frontrunner-scott-bessent-could-shift-wall-street-crypto">betting markets</a>, Bessent was a frontrunner with an 82% probability of securing the nomination. His appointment could significantly impact Wall Street and the crypto sector.
In October, Bessent assured that a new Trump administration would <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41308042/trump-adviser-defends-ex-presidents-economic-policies-strong-dollar-would-natural">support a strong dollar</a>, countering previous suggestions of a weaker dollar to boost exports.
Despite Elon Musk&#8217;s support for Howard Lutnick, <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump favored Bessent&#8217;s</a> business-as-usual approach.
In July, Bessent gained attention for his optimistic stance on cryptocurrency, suggesting he might support digital assets if confirmed. &#8220;Crypto is about freedom and the crypto economy is here to stay,&#8221; he stated at the time.
The latest 13F filing from Bessent&#8217;s Key Square Group fund shows a highly concentrated portfolio, with equal investments in two banking-focused ETFs: the SPDR S&amp;P Regional Banking ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>) and the SPDR S&amp;P Bank ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBE#NYSE">KBE</a>), each making up 50% of the fund.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42146895/are-you-rich-enough-to-benefit-from-trumps-tax-breaks-heres-how-much-youd-need-to-be-part-of-the-top-5">Are You Rich Enough To Benefit From Trump&#8217;s Tax Breaks? Here&#8217;s How Much You&#8217;d Need To Be Part Of The Top 5%</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Government

News

Regulations

Politics

Economics

Trump Picks Hedge Fund Exec Scott Bessent As Treasury Secretary: What President-Elect's Choice Means For America's Economic Future

APLMW

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

APLM

UBS analyst Jay Sole maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Sell and raises the price target from $14 to $16.

Price Target

Analyst Ratings

UBS Maintains Sell on Gap, Raises Price Target to $16

UBS analyst Mark Carden maintains BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) with a Buy and raises the price target from $102 to $108.

UBS Maintains Buy on BJ's Wholesale Club, Raises Price Target to $108

UBS analyst Steven Fisher maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Neutral and raises the price target from $404 to $462.

UBS Maintains Neutral on Deere, Raises Price Target to $462

UBS analyst Karl Keirstead maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Neutral and raises the price target from $275 to $360.

UBS Maintains Neutral on Salesforce, Raises Price Target to $360

Jefferies analyst Lloyd Byrne maintains Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Hold and raises the price target from $12 to $22.

Jefferies Maintains Hold on Bloom Energy, Raises Price Target to $22

Jefferies analyst Jonathan Petersen maintains SL Green Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) with a Hold and raises the price target from $70 to $72.

Jefferies Maintains Hold on SL Green Realty, Raises Price Target to $72

Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on November 18, 2024, it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the "SEC").
Ocean Biomedical is delayed in filing the Form 10-Q as a result of previously disclosed developments with respect to filing of its 10-K for the year ended December 31, 2023.
The current notice will have no immediate effect on the listing or trading of Ocean Biomedical's common stock on Nasdaq, although there can be no assurances that further delays in the filing of the Form 10-Q will not have an impact on the listing or trading of the company's common stock. On October 16, 2024, Staff notified the Company that since it failed to timely file its Form 10-K for the year ended December 31, 2023, and its Forms 10-Q for the periods ended March 31, 2024 and June 30, 2024, the Company's securities were subject to delisting. The Company is now delinquent in the filing its form 10-Q for the period ended September 30, 2024. Accordingly, this matter serves as an additional basis for delisting the Company's securities from The Nasdaq Stock Market. This is formal notification that the Nasdaq Hearings Panel (the "Panel") will consider this matter in their decision regarding the Company's continued listing on The Nasdaq Capital Market, which hearing is scheduled for December 16, 2024. The Company intends to file the delinquent Forms 10-Q and 10-K as soon as practicable.

OCEA

Ocean Biomedical Announces Receipt Of Notice From Nasdaq Regarding Late Filing Of Quarterly Report

DA Davidson analyst Gil Luria maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Neutral and raises the price target from $60 to $70.

PCOR

DA Davidson Maintains Neutral on Procore Technologies, Raises Price Target to $70

Chesapeake Utilities Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) ("Chesapeake Utilities" or the "Company") today announced that it has established an at-the-market equity offering program (the "ATM Program") under which it may, from time to time, sell shares of its common stock having an aggregate sales price of up to $100,000,000 (the "Shares"). Chesapeake Utilities has entered into an equity distribution agreement with each of RBC Capital Markets, LLC, Barclays Capital Inc., Janney Montgomery Scott LLC, Ladenburg Thalmann &amp; Co. Inc., Guggenheim Securities, LLC, Citizens JMP Securities, LLC, M&amp;T Securities, Inc., Maxim Group LLC, PNC Capital Markets LLC, and Siebert Williams Shank &amp; Co., LLC (collectively, the "Sales Agents"), as sales agents. Pursuant to the equity distribution agreement, sales of the Shares may be made in transactions deemed to be "at-the-market offerings," as defined in Rule 415 under the Securities Act of 1933, as amended, including by sales made directly on or through the New York Stock Exchange. Chesapeake Utilities intends to use the proceeds from the sales, if any, of the Shares for general corporate purposes, including, but not limited to, financing of capital expenditures, repayment of short-term debt, financing acquisitions, investing in subsidiaries, and general working capital purposes.

Offerings

Chesapeake Utilities Corporation Announces $100M At-The-Market Equity Offering Program

DA Davidson analyst Gil Luria maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Neutral and raises the price target from $90 to $135.

DA Davidson Maintains Neutral on NVIDIA, Raises Price Target to $135

DA Davidson analyst Gil Luria maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Neutral and raises the price target from $75 to $115.

ESTC

DA Davidson Maintains Neutral on Elastic, Raises Price Target to $115

<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42131449/with-gary-gensler-preparing-to-quit-in-2025-secs-crypto-cases-likely-to-quietly-go-away-amid-trumps-pro-bitcoin-stance-says-pantera-capitals-katrina-paglia">President-elect Donald Trump</a> needs to find someone else to replace US Securities and Exchange Commission chair Gary Gensler. 
The Details: According to <a href="https://www.bloomberg.com/news/articles/2024-11-22/robinhood-s-gallagher-drops-out-of-sec-chair-consideration?sref=TBDibEcD">Bloomberg</a>, Dan Gallagher, chief legal officer at Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) has removed himself from consideration as head of the SEC.
Gallagher expressed his intention to remain at Robinhood in an emailed statement. 
&#8220;It is always an honor to have your name in the mix for an incredibly important job like SEC Chairman. However, I have made it clear that I do not wish to be considered for this position,&#8221; Gallagher said.&nbsp;
&#8220;I am committed to Robinhood and our millions of customers who represent the new generation of retail investors.&#8221;
Read More: <a href="https://www.benzinga.com/general/social-media/24/11/42119493/rumble-eyes-buying-bitcoin-could-it-be-the-next-microstrategy">Rumble CEO Considers Bitcoin Investment, Engages Michael Saylor As Shares Rally</a>
Gallagher has been Robinhood's chief legal officer since 2020. He steered the company through the GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) meme stock saga and Trump considered him a top <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41212008/trump-considers-robinhood-exec-dan-gallagher-for-sec-chair-if-re-elected">contender for the position</a>. He was a Republican SEC commissioner from 2011 to 2015, and previously served in other senior roles in the agency. 
The crypto community favored Gallagher, feeling he would <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41876266/bitcoin-blasts-past-82000-buy-everything-you-can-says-bernstein">help to advance</a> pro-crypto regulatory change.
Among the other names being floated for SEC chair include: Robert Stebbins, the SEC's former general counsel; Paul Atkins, former SEC commissioner; and Brian Brooks, former <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42053981/trump-sec-pick-speculation-sends-this-altcoin-soaring-past-bitcoin-and-ethereum-in-daily-gains">cryptocurrency executive</a> and former acting comptroller of the currency. 
As for Gallagher, he will stay on as head legal counsel at Robinhood.&nbsp;
"I will remain a vocal and consistent advocate for positive change in our markets,&#8221; Gallagher said. He added that he is &#8220;excited to work with the incoming Trump Administration, including the next SEC Chairman and the SEC staff, to promote innovation and provide more opportunity for retail investors.&#8221;
Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Robinhood shares ended Friday's session up 4.45% at $36.65. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Image: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

Legal

HOOD

MKTX

Robinhood's Gallagher Bows Out Of SEC Chair Consideration Under Incoming Trump Administration

Jefferies analyst Omar Nokta maintains Navigator Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVGS#NYSE">NVGS</a>) with a Buy and maintains $20 price target.

NVGS

Jefferies Maintains Buy on Navigator Holdings, Maintains $20 Price Target

Despite widespread anticipation that NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)'s quarterly results would dictate Wall Street's year-end trajectory, the stock market delivered a robust weekly rebound — even in the absence <a href="https://www.benzinga.com/quote/NVDA/news">of its AI darling.</a>
While the semiconductor titan beat analyst expectations on both earnings and revenue for the third quarter, Nvidia's stock remained flat for the week.
Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), the parent company of Google, faced sharp turbulence. Shares tumbled after the U.S. Department of Justice called for the divestiture of Chrome in a bid to curb Google's dominance in search and digital advertising.
The sell-off wiped out over $120 billion in market capitalization on Thursday alone.
A <a href="https://www.benzinga.com/tech/24/11/42140450/doj-targets-google-chrome-poll-shows-64-oppose-alphabet-breakup-youtube-seen-as-top-prize">recent Benzinga poll indicates</a> 64% of respondents oppose breaking up Alphabet, with YouTube viewed as the company's most valuable asset.
On the economic front, <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42141413/us-business-activity-soars-to-31-month-highs-in-november-small-caps-rally-dow-tops-44000">U.S. private sector activity expanded significantly</a> in November, as reflected in S&amp;P Global's Purchasing Managers' Index surveys. The services sector, in particular, surged at its fastest pace since March 2022, while price pressures continued to recede, creating less headwinds for the Federal Reserve.
Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rally shows no signs of cooling, with the cryptocurrency notching its fourth consecutive week of gains and hovering around the <a href="https://www.benzinga.com/24/11/42130693/bitcoins-path-to-100k-inevitable-but-leverage-to-the-gills-warns-mike-novogratz-predicts-80k-correction-ahead">historic $100,000 threshold.</a>
The U.S. dollar also maintained its upward momentum, rising for the eighth straight week to <a href="https://www.benzinga.com/news/econ-s/24/11/42138717/dollar-hits-2-year-highs-as-europes-recession-signals-spark-euro-pound-sell-offs">reach two-year highs.</a> This latest rally, however, stemmed largely from external turmoil, as escalating geopolitical tensions between Russia and Ukraine, coupled with worsening economic momentum in Europe, triggered sharp weekly sell-offs in the euro and the British pound.
<h1 class="wp-block-heading">You might have missed…</h1>
<h1 class="wp-block-heading">Trump Backs Drilling</h1>
President-elect Donald Trump advocates for increased fossil fuel production with his &#8220;drill, baby, drill&#8221; policy. In contrast, Elon Musk, co-leader of the proposed Department of Government Efficiency (DOGE), envisions a future dominated by solar energy. UBS analysts recommend investors consider renewable energy stocks following their <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42130859/as-trump-backs-drill-baby-drill-his-doge-co-lead-elon-musk-believes-all-energy-generation-will-be-solar-heres-what-ubs-recommends-after-election-dip">election-induced market dip.</a>
<h1 class="wp-block-heading">Trump Crypto Clarity</h1>
Cathie Wood of Ark Invest anticipates the Trump administration will provide regulatory clarity for Bitcoin and other digital assets, potentially incorporating them into <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42136536/ark-invests-cathie-wood-says-team-trump-would-give-regulatory-clarity-for-bitcoin-and-other-digital-assets-which-they-may-put-in-the-treasurys-strategic-reserve">the Treasury&#8217;s strategic reserve</a>.
<h1 class="wp-block-heading">GM Eyes F1</h1>
General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) is reportedly preparing to enter Formula One in 2026, potentially partnering with Andretti Autosport. This move would mark GM&#8217;s first foray into F1, aligning with its global <a href="https://www.benzinga.com/24/11/42135392/general-motors-gears-up-for-potential-f1-entry-in-2026-report">motorsport expansion strategy.</a>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42137929/2025-us-economy-outlook-cloudier-than-normal-jpmorgan-says-boom-bust-scenarios">2025 US Economy Outlook &#8216;Cloudier Than Normal,&#8217; JPMorgan Says: Boom, Bust Scenarios</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Large Cap

Forex

Global

$BTC

GOOG

GOOGL

Wall Street Rebounds Without Its AI Darling's Boost, King Dollar Maintains Dominance While Bitcoin Defies Gravity: This Week In The Markets

Rosenblatt analyst Catharine Trebnick maintains Zoom Video Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) with a Buy and maintains $78 price target.

Rosenblatt Maintains Buy on Zoom Video Comms, Maintains $78 Price Target

Bill Gates outspent fellow billionaire Jeff Bezos to construct one of the <a href="https://www.benzinga.com/general/entertainment/24/09/40860724/bezos-doesnt-sunbathe-alone-on-his-25m-a-year-superyacht-as-he-hosts-kim-kardashian-leonard">most expensive yachts ever</a>. Yet, he doesn&#8217;t seem too keen on owning it for himself.
What Happened: The Microsoft co-founder, known for his <a href="https://www.benzinga.com/general/education/24/10/41580000/bill-gates-turns-69-5-things-you-might-not-know-about-microsoft-co-founder">emphasis on sustainable energy</a>, commissioned a superyacht to be made using fuel cells.
The groundbreaking vessel, known as Breakthrough, has completed its sea trials. It is also set to be sold after Gates passed on buying it, as <a href="https://luxurylaunches.com/transport/bill-gates-645-million-fuel-cell-superyacht-has-finally-completed-its-extensive-sea-trials-powered-by-liquid-hydrogen-stored-at-a-bone-chilling-423f-nearly-as-cold-as-outer-space-the-mammo.php">reported </a>by LuxuryLaunches.
The $645 million superyacht is powered by liquid hydrogen, and stored at -423 degrees Fahrenheit. That makes it nearly as cold as outer space.
Along with using hydrogen power to travel, the yacht&#8217;s amenities are powered with emission-free energy thanks to green hydrogen.
Breakthrough completed trials near Amsterdam. The boat now heads to Edmiston, a seller of luxury yachts.
Coming in at 390 feet long, the Breakthrough is not quite as long as Bezos&#8217; 417-foot Koru vessel. Recall how the Amazon.com founder had difficulty getting the $500-million boat <a href="https://www.benzinga.com/news/22/08/28385974/jeff-bezos-500-million-superyacht-has-been-relocated-after-bridge-controversy-avoids-getting-egged-i">out of a shipyard.</a>
The Koru, which has its own support vessel spanning 250 feet long, comes with estimated annual operating costs of $25 million.
Breakthrough comes with an even higher price tag and is the first superyacht to be fuel-cell powered. It also features many amenities fit for Gates: a library, movie theater, basketball court, pool and onboard fully equipped hospital.
You may not be a billionaire like Bill Gates, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/general/entertainment/24/10/41187322/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
What&#8217;s Next: Gates not taking ownership of the superyacht could take away from the huge fuel-cell accomplishment. Also, there are relatively few potential owners who can afford the $645 million price tag.
"The brief was to build the greenest and most environmentally advanced yacht ever built, without compromise," Edmiston CEO Jamie Edmiston previously said, as <a href="https://www.forbes.com.au/life/boats/first-look-at-game-changing-1-billion-hydrogen-superyacht/">reported </a>by Forbes. "It was a huge challenge, but one that the team has embraced and delivered on."
It is unknown why Gates decided not to take ownership of the superyacht he commissioned.
Gates, the sixth-richest person in the world, is worth an estimated $160 billion according to <a href="https://www.bloomberg.com/billionaires/?sref=TBDibEcD">Bloomberg</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/09/40778448/bill-gates-says-retirement-sounds-awful-how-warren-buffett-inspires-billionaire-to-keep-wor">Bill Gates Says Retirement &#8216;Sounds Awful,&#8217; How Warren Buffett Inspires Billionaire To Keep Working</a></li>
</ul>
Image via Flickr/ World Economic Forum

Education

Bill Gates Has Superyacht Powered By Liquid Nitrogen: It's Already For Sale After Sea Trials

The latest update is out from MIRA Pharmaceuticals, Inc. (MIRA). MIRA Pharmaceuticals has revised its employment agreement with CFO Michelle Yanez,...

MIRA Pharmaceuticals Adjusts CFO Salary, Sets Annual Meeting

MIRA stock rallies 154% on preclinical results for ketamine drug

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MIRA Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) stock is seeing massive gains on Monday after the pre-clinical-stage pharmaceutical company released data from its pre-clinical study of Ketamir-2.



Ketamir-2. is MIRA Pharmaceuticals&rsquo; novel oral ketamine analog. It&rsquo;s being studied as a potential <a href="https://finance.yahoo.com/news/mira-pharmaceuticals-reveals-preclinical-success-120000778.html">treatment for neurological and neuropsychiatric disorders</a>. That includes depression, treatment-resistant depression and post-traumatic stress disorder (PTSD).



Here&rsquo;s what MIRA Pharmaceuticals chairman and CEO Erez Aminov said about the new data.




&ldquo;Our vision at MIRA is to transform the treatment landscape for neurological and neuropsychiatric disorders. Ketamir-2 shows great promise in addressing these debilitating conditions with improved efficacy and safety, offering new hope and better quality of life for patients and their families. Importantly, we are seeing a drumbeat of promising data this year that we hope will allow us to file an IND and begin to test our theories about Ketamir-2 in actual patients in the near term.&rdquo;




<h2>What This Means for MIRA Stock</h2>



MIRA stock could benefit greatly if the company is able to move forward with its IND plans. The company&rsquo;s shares are already gaining today with more than 116 million shares traded. For the record, its daily average trading volume is about 654,000 shares.



MIRA Stock is up 318.1% as of Monday afternoon.



Investors will want to stick around for more of the most recent stock market stories!



We have all of the hottest stock market news investors need to know about on Monday! Among that is what has shares of Nio&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/nio-stock-quote/">NIO</a>), Reddit&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/rddt-stock-quote/">RDDT</a>) and Cassava Sciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sava-stock-quote/">SAVA</a>) stock moving today. All of that info is good to go at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/nio-stock-alert-more-details-emerge-about-upcoming-nio-day-2024/">NIO Stock Alert: More Details Emerge About Upcoming Nio Day 2024</a></li>



<li><a href="https://investorplace.com/2024/07/rddt-stock-alert-reddit-nabs-new-deals-with-nfl-nba/">RDDT Stock Alert: Reddit Nabs New Deals with NFL, NBA</a></li>



<li><a href="https://investorplace.com/2024/07/sava-stock-alert-cassava-sciences-pops-on-late-stage-trial-update/">SAVA Stock Alert: Cassava Sciences Pops on Late-Stage Trial Update</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-up-318-today/">Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic that traders are going to want to know about and we have all of the latest news on Tuesday morning!



Moving stocks this morning are earnings reports, a settlement agreement, the pricing of a public offering and more.



Let&rsquo;s get into that below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Warrantee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock is rocketing close to 254% alongside heavy pre-market trading.</li>



<li>Nature&rsquo;s Miracle (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmhi-stock-quote/">NMHI</a>) shares are soaring more than 122% with strong early morning trading.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) stock is surging nearly 78% with heavy early morning trading today.</li>



<li>Frequency Electronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/feim-stock-quote/">FEIM</a>) shares are rising almost 33% alongside its <a href="https://www.marketwatch.com/story/frequency-electronics-shares-climb-on-higher-4q-earnings-a32189da">Q4 earnings report</a>.</li>



<li>Mammoth Energy Services (NASDAQ:<a href="https://investorplace.com/stock-quotes/tusk-stock-quote/">TUSK</a>) stock is heading over 29% higher after <a href="https://www.nasdaq.com/press-release/cobra-acquisitions-llc-announces-settlement-agreement-prepa-2024-07-22">announcing a settlement agreement</a>.</li>



<li>ENGlobal (NASDAQ:<a href="https://investorplace.com/stock-quotes/eng-stock-quote/">ENG</a>) shares are gaining more than 22% without any clear news.</li>



<li>Wheeler Real Estate IT (NASDAQ:<a href="https://investorplace.com/stock-quotes/whlr-stock-quote/">WHLR</a>) stock is jumping over 20% with no news to report.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) shares are climbing more than 19% despite a lack of news on Tuesday.</li>



<li>SCYNEXIS (NASDAQ:<a href="https://investorplace.com/stock-quotes/scyx-stock-quote/">SCYX</a>) stock is getting an over 15% boost on a <a href="https://www.nasdaq.com/press-release/scynexis-receive-10-million-milestone-payment-gsk-triggered-delivery-completed-furi">$10 million milestone payment</a>.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) shares are up more than 13% on Tuesday morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>TransCode Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) stock is crashing more than 59% after <a href="https://www.nasdaq.com/press-release/transcode-therapeutics-inc-announces-pricing-public-offering-2024-07-22">pricing a public offering</a>.</li>



<li>Mira Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) shares are plummeting close to 31% <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-up-318-today/">after a massive rally yesterday</a>.</li>



<li>Brera (NASDAQ:<a href="https://investorplace.com/stock-quotes/brea-stock-quote/">BREA</a>) stock is diving nearly 25% with strong pre-market trading this morning.</li>



<li>CareMax (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmax-stock-quote/">CMAX</a>) shares are tumbling over 22% <a href="https://www.benzinga.com/news/24/07/39892411/caremax-shares-are-up-by-more-than-200-what-you-need-to-know">after a rally yesterday</a>.</li>



<li>Nukkleus (NASDAQ:<a href="https://investorplace.com/stock-quotes/nukk-stock-quote/">NUKK</a>) stock is taking a more than 19% beating after a recent rally.</li>



<li>Castellum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ctm-stock-quote/">CTM</a>) shares are sliding over 19% <a href="https://investorplace.com/2024/07/why-is-castellum-ctm-stock-moving-today/">alongside volatility yesterday</a>.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) stock is falling almost 16% as shares <a href="https://investorplace.com/2024/07/why-is-exicure-xcur-stock-down-27-today/">continue to come off a recent rally</a>.</li>



<li>Quoin Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/qnrx-stock-quote/">QNRX</a>) shares are dropping more than 15% today.</li>



<li>Polaris (NYSE:<a href="https://investorplace.com/stock-quotes/pii-stock-quote/">PII</a>) stock is slipping over 15% after <a href="https://www.marketwatch.com/story/polaris-stock-tumbles-11-after-earnings-fall-far-short-of-consensus-and-company-cuts-full-year-outlook-c3299335">missing earnings estimates</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares close out our pre-market stock movers down more than 14%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-23rd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Mira Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) stock is down on Tuesday as the clinical-stage pharmaceutical company&rsquo;s shares come off of a major rally on Monday.



Shares of MIRA stock closed out Monday&rsquo;s normal trading hours up 627.4%. That came alongside heavy trading with <a href="https://finance.yahoo.com/quote/MIRA/">more than 153 million shares traded</a>. For comparison, its daily average trading volume is about 3.2 million shares.



Mira Pharmaceuticals stock experienced this rally after releasing data from a <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-up-318-today/">pre-clinical study of Ketamir-2</a>. This is the company&rsquo;s novel oral ketamine analog designed to treat neurological and neuropsychiatric disorders.



The big news here is that the results were positive. This has the company excited about the prospect of furthering the development of Ketamir-2 and submitting an investigational new drug (IND) application for it.



<h2>MIRA Stock Movement on Tuesday</h2>



Considering the massive rally MIRA shares underwent yesterday, it makes sense they would give up some of those gains in the days to follow. This has the stock dropping 27.4% as of Tuesday morning.



Today&rsquo;s dip comes with more than 5.5 million shares changing hands this morning. That&rsquo;s already above its daily average trading volume but is well below yesterday&rsquo;s heavy trading.



Investors who are seeking out even more of the most recent stock market stories today will want to keep reading!



We have all of the hottest stock market news that traders need to know about on Tuesday! That includes everything happening with shares of TransCode Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) stock, Nature&rsquo;s Miracle&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nmhi-stock-quote/">NMHI</a>)&nbsp;stock and Warrantee&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock today. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-transcode-therapeutics-rnaz-stock-down-62-today/">Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/trade-of-the-day-buy-sentinelone-s-stock-amid-cybersecurity-carnage/">Trade of the Day: Buy SentinelOne (S) Stock Amid Cybersecurity Carnage</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-natures-miracle-nmhi-stock-up-94-today/">Why Is Nature&rsquo;s Miracle (NMHI) Stock Up 94% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-down-27-today/">Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?

Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more

MIRA Mira Pharmaceuticals files $100M mixed securities shelf

MIRA Pharmaceuticals files $100M mixed securities shelf

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Mira Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) just reported results for the second quarter of 2024.<ul><li>Mira Pharmaceuticals reported earnings per share of -11 cents. This was below the analyst estimate for EPS of -10 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mira-stock-earnings-mira-pharmaceuticals-for-q2-of-2024/">MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024

MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has shared an update. MIRA Pharmaceuticals, Inc. announces a significant leadership change as Michael Jerman...

MIRA Pharmaceuticals Appoints New Board Member and Chairman

AMAT

ASTS

ASXC

ATOS

BABA

BATL

BEEM

BEKE

BLDP

BLUE

BREA

CARA

CATX

CMAX

COCP

CSCO

CTRM

ESPR

FEIM

GLNG

GNLN

GOEV

GOLD

GRAB

HUYA

IPDN

JAGX

KNDI

LITE

MDAI

MMAT

MNDY

NCPL

NMHI

NNDM

NUKK

OGEN

OUST

PSFE

QNRX

RDDT

RNAZ

RRAC

SACH

SAVA

SCYX

SOAR

STNE

TAYD

TCEHY

TCRT

TUSK

VUZI

WHLR

WKHS

WRNT

XXII

Screenshot 2024-10-02 at 5.44.40 PM

Biotech

General

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

Screenshot 2024-09-18 at 6.27.57 PM

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

Screenshot 2024-09-04 at 6.19.41 PM

TELO

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Screenshot 2024-08-26 at 4.53.37 PM

The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End

Screenshot 2024-07-25 at 6.08.16 PM

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

Press Releases

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

Comments

Mira Pharmaceuticals

뉴스

에 대한 최신 뉴스 Mira Pharmaceuticals (NASDAQ:MIRA) 주식

금요일, 8월 02, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌